



**AN ACT CONCERNING COLLABORATIVE PRACTICE BETWEEN  
PHYSICIANS AND PHARMACISTS.**

Be it enacted by the Senate and House of Representatives in General Assembly convened:

1 Section 1. (NEW) (*Effective October 1, 2002*) (a) One or more  
2 pharmacists licensed under chapter 400j of the general statutes, who  
3 are determined eligible in accordance with subsection (c) of this  
4 section, and employed by a hospital may enter into a written protocol-  
5 based collaborative drug therapy management agreement with one or  
6 more physicians licensed under chapter 370 of the general statutes to  
7 manage the drug therapy of individual patients receiving inpatient  
8 services in a hospital licensed under chapter 368v of the general  
9 statutes in accordance with subsections (b) to (d), inclusive, of this  
10 section and subject to the approval of the hospital. Each patient's  
11 collaborative drug therapy management shall be governed by a  
12 written protocol specific to that patient established by the treating  
13 physician in consultation with the pharmacist.

14 (b) A collaborative drug therapy management agreement may  
15 authorize a pharmacist to implement, modify or discontinue a drug  
16 therapy that has been prescribed for a patient, order associated  
17 laboratory tests and administer drugs, all in accordance with a patient  
18 specific written protocol. In instances where drug therapy is  
19 discontinued, the pharmacist shall notify the treating physician of such  
20 discontinuance no later than twenty-four hours from the time of such  
21 discontinuance. Each protocol developed, pursuant to the collaborative

22 drug therapy management agreement, shall contain detailed direction  
23 concerning the actions that the pharmacists may perform for that  
24 patient. The protocol shall include, but need not be limited to, (1) the  
25 specific drug or drugs to be managed by the pharmacist, (2) the terms  
26 and conditions under which drug therapy may be implemented,  
27 modified or discontinued, (3) the conditions and events upon which  
28 the pharmacist is required to notify the physician, and (4) the  
29 laboratory tests that may be ordered. All activities performed by the  
30 pharmacist in conjunction with the protocol shall be documented in  
31 the patient's medical record. The pharmacists shall report at least every  
32 thirty days to the physician regarding the patient's drug therapy  
33 management. The collaborative drug therapy management agreement  
34 and protocols shall be available for inspection by the Departments of  
35 Public Health and Consumer Protection. A copy of the protocol shall  
36 be filed in the patient's medical record.

37 (c) A pharmacist shall be responsible for demonstrating, in  
38 accordance with this subsection, the competence necessary for  
39 participation in each drug therapy management agreement into which  
40 such pharmacist enters. The pharmacist's competency shall be  
41 determined by the hospital for which the pharmacist is employed. A  
42 copy of the criteria upon which the hospital determines competency  
43 shall be filed with the Commission of Pharmacy.

44 (d) The Commissioner of Public Health, in consultation with the  
45 Commissioner of Consumer Protection, may adopt regulations in  
46 accordance with chapter 54 of the general statutes, concerning the  
47 minimum content of the collaborative drug therapy management  
48 agreement and the written protocol and as otherwise necessary to  
49 carry out the purpose of this section.

This act shall take effect as follows:	
Section 1	<i>October 1, 2002</i>

**PH**      *Joint Favorable Subst.*